Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)
July 25, 2022 07:15 AM EDTUpdated 12:33 PM
Deals
China

Low-pro­file start­up stakes its claim to Sanofi's siR­NA plat­form in wake of set­backs

John Carroll

Editor & Founder

A biotech in Chi­na re­ports to­day that it will be scoop­ing up a string of pre­clin­i­cal siR­NA pro­grams from Sanofi as the multi­na­tion­al play­er lat­er­als …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mod­er­na re­ports slow start to RSV sales as Ban­cel steps back from com­mer­cial role

Sarep­ta dis­con­tin­ues work on next-gen ex­on-skip­ping drug for Duchenne

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Joe Jimenez's lat­est Adi­tum com­pa­ny lines up T cell en­gager from Chi­na

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times